{"name":"Janssen-Cilag Pty Ltd","slug":"janssen-cilag-pty-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Galantamine (Reminyl)","genericName":"Galantamine (Reminyl)","slug":"galantamine-reminyl","indication":"Mild to moderate Alzheimer's disease","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tacrolimus With Diet and Exercise Intervention","genericName":"Tacrolimus With Diet and Exercise Intervention","slug":"tacrolimus-with-diet-and-exercise-intervention","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Galantamine (Reminyl)","genericName":"Galantamine (Reminyl)","slug":"galantamine-reminyl","phase":"marketed","mechanism":"Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, and also acts as an allosteric modulator of nicotinic receptors to enhance cholinergic neurotransmission.","indications":["Mild to moderate Alzheimer's disease"],"catalyst":""},{"name":"Tacrolimus With Diet and Exercise Intervention","genericName":"Tacrolimus With Diet and Exercise Intervention","slug":"tacrolimus-with-diet-and-exercise-intervention","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxONlpCeFJXYndnQlB0ckJOUHZROG41RzdoY2NzeFBwcUc1ejFTMXROTE9IZHRpY1JJUlRadVlmeVVua2tOR2ZaYzFHLVdJLU9wdE5oYzlINURtNS12U1pMQ1RwTHRwYkhoV3o3MlU4NXhuaEZIaEhBYXdJVXptZXBpMERBWWZmUTVva0dRR2tvbE00eTFjaVNV?oc=5","date":"2026-02-27","type":"trial","source":"Market Data Forecast","summary":"Schizoaffective Disorders Treatment Market Size, 2034 - Market Data Forecast","headline":"Schizoaffective Disorders Treatment Market Size, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQbHFuMTFKc0Zpd29fXzZiQ0JVc2ViRGYxM2V4RnU3VmdrTlFkdEdNdlZzX2pJX2RkZ2h2ZkxCOF91NEgwd21zWVlTNUpPX3ZGSnlQdnVIbUl2X3dIcWdOTE1NczYzTjItSUVhTmExcVRjWHg0WE9jenN4ZVJRQmZhYW1QeUlzQVRkeFhWY2tDcjZ5VlNOSGxuUkFNS1dsY0RJdXpFZEEzal8zNmdjT0pMV0Q4Wi16czJLM1BjcUtJYzZFTXZzVUhJTVpqTjBpVVhXRndGamE2NA?oc=5","date":"2025-12-17","type":"patent","source":"Pearce IP","summary":"Federal Court of Australia Awards Janssen First Pharmaceutical Patent Preliminary Injunction in 7 Years - Pearce IP","headline":"Federal Court of Australia Awards Janssen First Pharmaceutical Patent Preliminary Injunction in 7 Years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPb0o0N2FtYVBXTUp0Um5hcGtBTC1vRmpmZkRIRGlNNUVJdkhvYnFmQ3JNQTlsQzBWS2ZjTk1SbThqbmlDczllMDcyLVg4R2tDejFLcWFWaVdFOWF2dWxCN2gzbVZBdlVkbzdtX1FPek5BREZLbTNxU0lnZ1U2M2xKNHkyaHBYZUNjU3RrLWpB?oc=5","date":"2025-10-10","type":"pipeline","source":"Frontiers","summary":"Unlocking the potential of immunotherapy for patients with resectable non–small cell lung cancer - Frontiers","headline":"Unlocking the potential of immunotherapy for patients with resectable non–small cell lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNMjVkdDZGZ1hUMURQVWczOWVkSkNGeUd5WVkyUXRKeGJCZWFPYkRsM1Z0bFh3MC1CRTB5b2ExNDh6UV9OTllObHZhN0JYbGZFN3Jpc0E5RFBkMmZNUzZad0lOaHdqdklLQUtVbVF1VmRZdzVBOWFuZzdFYVNpS2ppVk1FanFYU0VEZXhRaHhXM0g1MDctb0xWTTB4VXd1dFl1U0NBS3BERTRGZm1fSTlMVEJfNkN6Q1FqVzYwblFfOXE4VW9kdmhhdlc5QjJCam5BX3MwMkoyakNkOFYyelkxV0VR?oc=5","date":"2025-06-17","type":"pipeline","source":"PR Newswire","summary":"Chronic Hepatitis B Market--The US to Have the Lion's Share Among the 7MM, Predicts DelveInsight - PR Newswire","headline":"Chronic Hepatitis B Market--The US to Have the Lion's Share Among the 7MM, Predicts DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOOGtzUHNmN0hwalJEWHY5a0xxT0d6ajNSWU9DZTQ0Y2p0Z2piSExIN0pYTmNMUS14YWx2WmpUVVA0ekVyejlKc2diRHdSd3VFTW5MbUlTN3FKSzc4STJFenA5R1RLbDY2MUhSLVZrUjkyUXRPUXR5VXUzR2wxOVBjOWNaVmpRVVVjLTZhdEJHSjNfSmJwVFpPM0p1aFVhWU9yWmNvaXRFOWd1aUpY?oc=5","date":"2025-06-09","type":"pipeline","source":"Medscape Reference","summary":"Addressing Partial Treatment Response in MDD Patients - Medscape Reference","headline":"Addressing Partial Treatment Response in MDD Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOREpwaVgwQy1WaTNlR0dTT01ycGFKbVNlWVRzS2RGblRjOTkxMGNHZjhOMjVONUFkTjJUN0R6ZGZpRDZpNGJPS2tNS1d1b3g0LURPZXdGZG1LM0xhVjJOckdBMk9QSy0xaFNiZGFHZEhKeXBYcWprTG1HcWJqWVQ2VEsxWDRiYkQ5a0R6eXNzd2RuTS1QZWh3Yk10bXlOM0ZpT05rSVNNcHRaNTY5NXBmd0l0LTg?oc=5","date":"2025-02-25","type":"patent","source":"Pearce IP","summary":"The Right Dose: Opposition to Janssen’s Dosing Regimen Patent Amendments Denied - Pearce IP","headline":"The Right Dose: Opposition to Janssen’s Dosing Regimen Patent Amendments Denied","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNc0Mxblg5LUVQMHhyem0tV0swemI2ZnViSGNFT3pMTE9RMmI0elU1VVlpcm1PR19MT3NKX2duTU1Jb1VxNWh1a3ZrWGEyNTR3b1Z6WFRJbWo1VHpWUnJvMTFqMlFWTUhYaEZ2UXVSSmJFWERnSlJIUHM1c29CS29mR3pfajlJTERZZzFkMHdsemd0QW9vNWJCaXBsRQ?oc=5","date":"2025-02-06","type":"pipeline","source":"Grand View Research","summary":"U.S. Dry Eye Syndrome Treatment Market Size Report, 2030 - Grand View Research","headline":"U.S. Dry Eye Syndrome Treatment Market Size Report, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQdDJQSnRIVUhoeTNjQlNGekFFQUF1Mnh6ZkE3cEpSTlZ4RXRiVmh6UHMtcDhTbldyazJmcWZxdl94dkxYc2piUWhhVGJqdUE0dlRaYmhRN29qOTlFOWwxd09TQnFyQUh1VEFUQlZiQjd1cjRWdGFMOUViSnMtZGJ5VDdGUF9TTV92Z3I5a3N6b2xMVXQ2?oc=5","date":"2024-04-23","type":"patent","source":"WilmerHale","summary":"Federal Circuit Patent Watch: District Court’s “Seemingly Siloed and Inflexible Approach” to Obviousness “Ran Afoul” of KSR - WilmerHale","headline":"Federal Circuit Patent Watch: District Court’s “Seemingly Siloed and Inflexible Approach” to Obviousness “Ran Afoul” of ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9TcWZTV1hpdU11dDdrNEN2MVpOejNUdU85cjlfbF9ad2hrUk41REhPanV3T0x3b05CR1pGYWFDcmd5SWNvVlJhWVBUNVF2cDd4eWY0ci1VbTVjelc2RnFv?oc=5","date":"2024-03-07","type":"trial","source":"nature.com","summary":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial | Molecular Psychiatry - natur","headline":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1FdEVvUDk0ek1mT19CRkJTSHFLaXlwbFJRdXgtLTFmQlQyX1BOVDExRERDbDFnam93ZG9DcnpMTGU0Q1h2VTNCakJYVzJqd0phcS15Y1dBQW5FUmtBVTVHYnhMMG1CLTU5azQ4UA?oc=5","date":"2023-11-11","type":"trial","source":"Wiley Online Library","summary":"Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia - Wiley Online Library","headline":"Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxQNE1UR2NUaGFDMGJNQ3pFTl91YmY1QlE4Q2U4QVJoZmdIV0Q4OTRMNDJDTi1SU1F6SUxGUTFfQ2o0aXZxX0NHZ1dCUDhZYjA4bzZVWk1WaEptWkd3aXF4Sl9vUW9yX0w5NzBndFdvV214RlByV3BWTTM5OWM0QW9lRE50dVVzbG1xMkNFRGlYRndvanh2dl9TekpxdmE3Yk1KeUtUblo5Q09ibzBGcG1aSnFOZDJTQmQtOGpDbGJXU0NqYUNXaW52VkhkVUxfaWZrUFNzYld3OHF3NEttRnBCX2xodTEycTE4bU1EZkpURjllWl9aeHRxNk9WNmlZVGYxR2hncFFZckJjTWo0TThoa2F2Ym5HUHI3RHlmTkRRNEVKcjFyNWJGSFZhdmZ3YVkyTVl5VWpwczByMUJpNFpjWTRGMWVscHN5Wjk4ZVdNbUFCckVTODFBQkJ3aG1rYW1GXzlKRg?oc=5","date":"2021-07-14","type":"deal","source":"Monash University","summary":"Johnson & Johnson Innovation announces extension of innovation partnering office at Monash University in collaboration with Victorian State Government to accelerate the life-sciences hub - Monash Univ","headline":"Johnson & Johnson Innovation announces extension of innovation partnering office at Monash University in collaboration w","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNem1SMHgxYkxybDJNcEhiN3pGUkNrTm4tNHRaSzZhcHBibGlFZDB0WU5VMXExU1pQUTBYeEJJY1BVSjljNThwb3V3T0NmeXU2YjRtcEFTMFdCd2V2ZWFhWXhVR3ExWGRvT1FUaG4zb05NQnlQRjJLM2I2QUFHZ1o5d0lTd2x5bHFmT05Gak1EWjQxVnZsUW4yYmc4am9OdG80V284enpCa2NJRVlhTWtjWm1uQzZucEFC?oc=5","date":"2020-10-15","type":"pipeline","source":"BioSpectrum Asia","summary":"Chris Hourigan steps in as Company Group Chairman for Janssen APAC - BioSpectrum Asia","headline":"Chris Hourigan steps in as Company Group Chairman for Janssen APAC","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}